Length:
91 pages

Date Published: 
November 2010

Print copies are available upon request.  Call 781-972-5444. 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

The Antiviral Pipeline: HIV, HCV, and Influenza - Table of Contents

Author: Leslie A. Pray, PhD

Executive Summary 

Chapter 1
INTRODUCTION
1.1. An Overview of Antiviral Drug Development
1.2. Resistance as a Major Driver of Antiviral Drug Development
 

Chapter 2
THE ANTI-HIV DRUG PIPELINE
2.1. An Overview of the Anti-HIV Antiviral Market and Promising Candidates in Late-Stage Development
2.2. HIV Drugs on the Market
2.3. The Nucleoside Reverse Transcriptase Inhibitor (NRTI) Pipeline
2.4. The Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Pipeline

Rilpivirine
2.5. The Protease Inhibitor Pipeline
2.6. The Fusion and Attachment Inhibitor Pipeline

Vicriviroc
2.7. The Integrase Inhibitor (INI) Pipeline
2.8. Combination Therapies in the Pipeline
2.9. Interview with Roger Tung, PhD; President and Chief Executive Officer; Concert Pharmaceuticals; Lexington, MA
 

Chapter 3
HEPATITIS C: THE NEXT BIG MARKET?
3.1. Overview of the HCV Antiviral Market
3.2. Current Antiviral Therapies for Chronic HCV
3.3. Searching for New Therapies
3.4. Development Activity by Target
New Interferons
Pegylated Interferon Lambda
Albinterferon Alfa-2b
3.5. The Protease Inhibitor Pipeline
Telaprevir
Boceprevir
IDX320
3.6. The Polymerase Inhibitor Pipeline
3.7. Targeting the Host
3.8. The Cyclophilin Inhibitor Pipeline
3.9. Combination Therapy Without Interferons and Ribavirin: A True Paradigm Shift in HCV Treatment
 

Chapter 4
INFLUENZA ANTIVIRALS
4.1. Overview of Influenza and the Influenza Antiviral Market
The Reality of Resistance
Other Limitations of Currently Available Influenza Drugs
4.2. Filling an Unmet Medical Need: Intravenous Peramivir Therapy for Seriously Ill Patients
4.3. CS-8958: A Long-Lasting Neuraminidase Inhibitor with a Simplified Dosing Regimen
4.4. Potentially First-in-Class Polymerase Inhibitor T-705
4.5. Other Influenza Antivirals in Earlier-Stage Development
DAS181 (Fludase): A Novel Broad-Spectrum, Entry-Blocker Approach to Treating Influenza
A Novel Inhaled Therapy, PUR003
A Passive Antibody Approach to Influenza Treatment and Prevention
4.6. A Novel Approach for Treating the Flu: The Potential for Combination Therapy
4.7. Interview with David Wurtman, MD, MBA; Vice President, Corporate Development; NexBio; San Diego, CA
 

Chapter 5
ANTIVIRAL DRUG DEVELOPMENT: FUTURE TRENDS
5.1. The Future of HIV Antiviral Drug Development
The Evolution of Resistance Will Continue to Demand—and Drive—Innovation in HIV Antiviral Development
Sales of Generic HIV Drugs Will Grow
5.2. More on the Future of HCV Antiviral Drug Development 
HCV Patients with Co-Morbidities: An Unmet Medical Need
5.3. The Future of Influenza Antiviral Development
5.4. Meeting Other Unmet Antiviral Needs
The Poliovirus Pipeline
West Nile Virus
Smallpox
5.5. Conclusion 

References 

Company Index with Web Addresses